1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
83rd OREGON LEGISLATIVE ASSEMBLY--2025 Regular Session
House Bill 2599
Sponsored by Representative PHAM H (Presession filed.)
SUMMARY
The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject
to consideration by the Legislative Assembly. It is an editor’s brief statement of the essential features of the
measure as introduced.The statement includes a measure digest written in compliance with applicable readability
standards.
Digest: Tells PDAB to make a plan about uniform drug pricing and report back. (Flesch Read-
ability Score: 76.5).
Requires the Prescription Drug Affordability Board to make recommendations to the Legislative
Assembly regarding aligning prescription drug price transparency.
Sunsets on January 2, 2027.
Takes effect on the 91st day following adjournment sine die.
A BILL FOR AN ACT
Relating to the Prescription Drug Affordability Board; and prescribing an effective date.
Be It Enacted by the People of the State of Oregon:
SECTION 1. The Prescription Drug Affordability Board established in ORS 646A.693 shall
develop a plan that consolidates and aligns the objectives of the Prescription Drug
Affordability Board and the Prescription Drug Price Transparency Act. No later than De-
cember 15, 2026, the board shall submit a report to the interim committees of the Legislative
Assembly related to health, in the manner provided in ORS 192.245, that includes recom-
mendations for legislation that:
(1) Ensures the work of the Prescription Drug Affordability Board focuses on the pre-
scription drugs, reported through the Prescription Drug Price Transparency Act, that are:
(a) Increasing in price by more than 10 percent from one year to the next;
(b) Reported as the top 25 prescription drugs in year-over-year health plan spending in-
creases; or
(c) Reported as the top 25 prescription drugs with the highest overall health care spend-
ing;
(2) Aligns all reporting requirements for prescription drugs that are:
(a) Increasing in price by more than 10 percent from one year to the next;
(b) Reported as the top 25 prescription drugs in year-over-year health plan spending in-
creases;or
(c) Reported as the top 25 prescription drugs with the highest overall health care spend-
ing;
(3) Identifies entities within the prescription drug supply chain that should be included
in transparency reporting requirements established by the Prescription Drug Price Trans-
parencyAct;
(4) Ensures prescription drug price transparency reporting requirements are consistent
through the prescription drug supply chain;
(5) Ensures trade secrets and confidential information are protected, including by en-
NOTE:Matter in boldfaced type in an amended section is new; matter [italic and bracketed] is existing law to be omitted.
New sections are in boldfaced type.
LC 3116 HB2599
1
2
3
4
5
6
7
8
suring that prescription drug pricing data can be reported in an aggregated form; and
(6) Makes additions to the requirements for membership of the Prescription Drug
Affordability Board, as described in ORS 646A.693, to reflect representation of stakeholders
subject to prescription drug price transparency reporting.
SECTION 2. Section 1 of this 2025 Act is repealed on January 2, 2027.
SECTION 3.This 2025 Act takes effect on the 91st day after the date on which the 2025
regular session of the Eighty-third Legislative Assembly adjourns sine die.
[2]